ECE 2019: type 2 diabetes and hearing loss prevalence


  • Mary Corcoran
  • Univadis Medical News
El acceso al contenido completo es sólo para profesionales sanitarios registrados. El acceso al contenido completo es sólo para profesionales sanitarios registrados.

Four out of five adult patients with type 2 diabetes (T2D) have some degree of hearing loss, according to a new research being presented at the 21st European Congress of Endocrinology (ECE) this week. 

In a new study, researchers recruited 200 patients aged between 30 and 60 years with T2D. The patients were divided into two groups: Group one (n=151) included those with moderate to severe distal sensory-motor neuropathy (Michigan Diabetic Neuropathy Score [MDNS] >12) and group two (n=49) included those with no neuropathy (MDNS score

Overall, the prevalence of any hearing loss (AHL) was 81 per cent. The prevalence was 85.5 per cent among those with neuropathy and 66.6 per cent among those without neuropathy. The prevalence of clinically significant hearing loss (CSHL) (moderate and above) was 28.5 per cent overall, 30.5 per cent with neuropathy and 22.8 per cent without neuropathy.

On multivariate binary logistic regression with AHL in any one ear as outcome, the authors found significant correlation with age, gender, taking regular ACE inhibitors and MDNS score.